icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin
 
 
  Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
 
David Bernstein1, Yan Luo2, Jacob Lalezari3, David Wyles4, William King5, Naoki Tsai6, Mitchell Davis7, Thomas Sepe8, Jeff rey Fessel9, Marti n King2, Thomas Podsadecki2, Curti s Cooper10
1North Shore University Hospital, Manhasset, New York, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Quest Clinical Research, San Francisco, California, United States; 4University of California San Diego, La Jolla, California, United States;
5Trial Management Associates, LLC, Wilmington, North Carolina, United States; 6Queens Medical Center, University of Hawaii, Honolulu, Hawaii, United States; 7Digesti ve Care, South Florida Center of Gastroenterology, Wellington, Florida, United States;
8University Gastroenterology, Providence, Rhode Island, United States; 9Kaiser Permanente, San Francisco, California, United States; 10Ott awa Hospital Research Insti tute, Ott awa, Ontario, Canada

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif